Management of Acute Bleeding Due to Vitamin K Deficiency
For severe bleeding with elevated INR (>1.5, or >1.2 for intracranial hemorrhage), immediately administer prothrombin complex concentrate (PCC) at 25 IU/kg (or dose based on INR) combined with 10 mg vitamin K (IV or PO) to reduce mortality by half. 1
Severity-Based Treatment Algorithm
Severe/Life-Threatening Bleeding
Immediate reversal is critical - the most recent 2025 French guidelines demonstrate that early reversal with PCC plus vitamin K reduces mortality by 50% in patients with serious bleeding, including intracranial hemorrhage 1.
Treatment protocol:
- Stop anticoagulation immediately
- Administer PCC: Dose based on INR if available quickly:
- Concurrent vitamin K 10 mg (IV slow infusion over 15-30 minutes OR oral) 1
Critical distinction: PCC is strongly preferred over fresh frozen plasma (FFP). A randomized trial of 202 patients showed PCC corrects INR more rapidly than FFP, and for intracranial hemorrhage specifically, PCC reduces hematoma expansion risk better than FFP 1. FFP requires high doses (>30 mL/kg) and carries volume overload risk 1.
INR Monitoring Post-Reversal
Check INR at specific intervals to guide additional therapy 1:
- Within 30 minutes post-PCC
- At 6-8 hours
- At 24 hours
This monitoring determines need for additional PCC or vitamin K doses, as PCC effect is transient (lasting only hours) while vitamin K provides sustained correction 1.
Non-Severe Bleeding
For non-severe bleeding, vitamin K alone is sufficient - do NOT use PCC 1:
- Investigate and correct overdose causes (medication errors, renal insufficiency, drug interactions)
- Administer vitamin K without PCC
- Initiate symptomatic/hemostatic treatment
- Reassess treatment effect
Elevated INR Without Bleeding
The approach varies by INR level 3:
INR 5-9 without bleeding:
- Omit 1-2 warfarin doses
- If increased bleeding risk: give oral vitamin K 1-2.5 mg
- Resume warfarin at lower dose when INR therapeutic
INR ≥9 without bleeding:
- Give oral vitamin K 3-5 mg
- Anticipate INR fall within 24-48 hours
- Monitor closely and repeat vitamin K as needed
INR >10 without bleeding:
- Oral vitamin K 1-2.5 mg plus hold warfarin 4
- Avoid high-dose vitamin K (creates hypercoagulable state and warfarin resistance) 4
Important Clinical Pitfalls
Vitamin K dosing nuances:
- 10 mg dose is appropriate for severe bleeding but may delay warfarin re-anticoagulation postoperatively 1
- 5 mg dose preferred for semi-urgent procedures when anticoagulation will be resumed 1
- Never use subcutaneous route - absorption is unpredictable 2
PCC considerations:
- Four-factor PCC (4F-PCC) contains all vitamin K-dependent factors (II, VII, IX, X) and is FDA-approved for warfarin reversal 2
- Three-factor PCC requires FFP supplementation for factor VII 5
- Thrombotic risk with PCC is low (~1.8%) 1
- PCC contains 25x the concentration of clotting factors compared to plasma, allowing smaller volume and faster infusion 2
Do not delay treatment for INR results in severe bleeding - initiate hemostatic treatment immediately while awaiting laboratory confirmation 1.
Tranexamic acid should be administered according to same indications as non-anticoagulated patients (though evidence is mixed for intracranial hemorrhage) 1.
Supportive Care Essentials
- Address underlying bleeding source with appropriate procedures
- Consider packed red blood cells if significant blood loss occurred 3
- Monitor carefully to avoid pulmonary edema in elderly or cardiac patients 3
- Establish multidisciplinary protocols for rapid PCC access from pharmacy 1
Anticoagulation Resumption
After high-dose vitamin K administration, bridging with heparin may be necessary until warfarin responsiveness returns, as vitamin K effects must reverse before warfarin becomes effective again 3. The 30-day ischemic stroke risk after warfarin discontinuation is 3-5%, so resumption timing requires individualized assessment balancing bleeding versus thrombotic risk 6.